Tradestie Institutional Equity Comparison Engine
RNA vs GOCO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
RNA Overall Edge
RNA Captures Institutional Edge (3โ0 Pillars ยท 7โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avidity Biosciences, Inc. Common Stock (RNA) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, RNA trades at N/M Forward P/E with -194.8% operating margin (+24.2% YoY revenue) versus GOCO at N/M Forward P/E and -292.0% operating margin (-94.6% YoY). In options structure, RNA sits in UNCLASSIFIED (2nd %ile IV; Dealer Gamma Walls on Pro) against GOCO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
RNA N/M vs GOCO N/M Fwd P/E
Growth & Margin Winner
RNA
Op Margin -194.8% vs -292.0% ยท YoY +24.2% vs -94.6%
Momentum & Technical Winner
RNA
1Y -90.8% vs -94.8% ยท 52W Pos 0% vs 0%
Options & Structure Winner
RNA
UNCLASSIFIED (2nd %ile IV) vs UNCLASSIFIED (N/A IV)
RNA
NASDAQ
Avidity Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$6.51
+1.32% 1D
Market Cap
$162.0M
1M Return
-14.39%
1Y Return
-90.8%
Forward P/E
N/M
Unified AI Score
47.4 / 100
HOLD
Tech 35.0
Fund 49.0
Flow 61.0
Mom 55.0
GOCO
NASDAQ
GoHealth, Inc. Class A Common Stock
Insurance Agents, Brokers & Service
$0.30
+5.14% 1D
Market Cap
$8.5M
1M Return
-64.69%
1Y Return
-94.78%
Forward P/E
N/M
Unified AI Score
42.9 / 100
HOLD
Tech 40.0
Fund 46.0
Flow 50.0
Mom 48.9
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
RNA -90.8%
GOCO -94.78%
Spread: +6.29 pp (RNA Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
RNA TTM Op. Margin: -194.8%
GOCO TTM Op. Margin: -292.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RNA vs GOCO. Trailing 12-month operating profitability (RNA -194.8% vs GOCO -292.0%) and valuation multiples (RNA N/M vs GOCO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | RNA | GOCO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $162.0M | $8.5M | Larger Scale | RNA |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +24.2% | -94.6% | Higher Growth | RNA |
| Operating Margin (TTM) Profitability | -194.8% | -292.0% | Higher Margin | RNA |
| Net Profit Margin Profitability | -180.9% | -189.7% | Higher Margin | RNA |
| Return on Equity (ROE) Capital Efficiency | -95.0% | -289.9% | Higher ROE | RNA |
| 52-Week Range Position Momentum | 0% ($6โ$73) | 0% ($0โ$7) | Stronger Trend | Tie |
| Beta / 30D Volatility Risk Regime | 1.05ฮฒ ยท 63% Vol | 2.15ฮฒ ยท 201% Vol | Lower Realized Risk | RNA |
| Unified Institutional Score Composite Signal | 47.4 / 100 (HOLD) | 42.9 / 100 (HOLD) | Higher Composite | RNA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full RNA vs GOCO Buy Guide
RNA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
2nd %ile
IV Regime
Compressed (<25th %ile)
GOCO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither RNA nor GOCO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.